Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T cell therapy plus peginterferon in metastatic malignant melanoma
2014-001420-29Phase 2Terminated
- Sponsor
- Center for Cancer Immune Therapy
- Start
- Apr 2014
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in melanoma, sponsored by Center for Cancer Immune Therapy. Primary endpoint: Toxicity. Started Apr 2014; status: terminated.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-001420-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001420-29.